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Background: Papillon-Lefèvre Syndrome (PLS) is a type IV genodermatosis caused by mutations in cathepsin C
(CTSC), with a worldwide prevalence of 1–4 cases per million in the general population. In México, the prevalence
of this syndrome is unknown, and there are few case reports. The diagnosis of twenty patients in the state of
Sinaloa highlights the need to characterize this syndrome in Mexicans.
Methods: To understand the basis of PLS in Mexicans, the gene expression, enzymatic activity and mutational
analysis of CTSC were assayed in nine PLS patients and their relatives. Frequencies of CTSC gene polymorphisms
and HLA alleles were determined in these patients, their relatives, and the population.
Results: Patients showed normal CTSC gene expression, but a deep reduction (up to 85%) in enzymatic activity in
comparison to unrelated healthy individuals. A novel loss-of-function mutation, c.203 T > G (p.Leu68Arg), was found
in all patients, and some carried the polymorphism c.458C > T (p.Thr153Ile). Allelic frequencies in patients, relatives
and controls were 88.89%, 38.24% and 0.25% for G (c.203 T > G); and 11.11%, 8.82% and 9.00% for T (c.458C > T).
HLA-DRB1*11 was found significantly more frequent (P = 0.0071) in patients than controls (33.33% vs. 7.32%), with
an estimated relative risk of 6.33.
Conclusions: The novel loss-of function mutation of CTSC gene (c.203 T > G) found in patients correlated with their
diminished enzymatic activity, and HLA-DRB1*11 was found to be associated with PLS. The study of more PLS
patients may give more insights into the etiology of the disease as well as its prevalence in México.
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Papillon-Lefèvre Syndrome (PLS) is an autosomal recessive
disorder that is caused by mutations in cathepsin C (CTSC)
(OMIM #245000). PLS is characterized by palmoplantar
hyperkeratosis and aggressive periodontitis, has a world-
wide prevalence of 1–4 cases per million in the general
population, and is often related with consanguinity [1-3].
Dermatological disorders initiate with erythema and after
about six months, they progress to hyperkeratosis of soles,
palms, knees and elbows [4]. This exacerbates in winter,* Correspondence: ramospayan@yahoo.com.mx
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distribution, and reproduction in any mediumleading to painful fissures. Aggressive periodontitis begins
with the primary dentition, leading to periodontium de-
struction, and the premature loss of deciduous teeth by age
of 6 years; afterwards gums heal, until the development of
the permanent dentition, when periodontitis reappears and
teeth are prematurely lost by the age of 16-years [5]. Besides
these basic features, PLS patients can present with liver
abscesses [6-9], increased incidence of pyogenic infections
[10], or mental retardation [11]. Medication for hyperkera-
tosis and periodontal care improve quality of life [12,13].
The CTSC gene (11q14.2) spans 4.7 kb and has seven
exons [14,15]. CTSC gene mutations have been reported
as responsible for PLS [14], as well as similar conditions
such as Haims-Munk Syndrome, and juvenile perio-
dontitis [16,17]. CTSC is expressed at high levels ined Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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skin, kidney, and placenta, and at moderate or low levels in
a variety of other organs. Gene structure shows several
possible tissue-specific regulatory elements.
CTSC (EC 3.4.14.1) or dipeptidyl peptidase I (DPPI) is a
lysosomal cysteine protease that removes dipeptides from
the free N-termini of protein and peptides. The CTSC gene
encodes a polypeptide chain that folds into an exclusion
domain, a propeptide, and two papain-like domains [18,19].
The active CTSC is a tetramer (200 kD) [20,21], while
cathepsin B, H and L are monomers [21-25]. CTSC plays a
major role in the cleavage of some hormones (including
glucagon, gastrin and angiotensin II), and the activation of
granule serine proteases from cytotoxic T lymphocytes,
natural killer cells (granzymes A and B), mast cells
(tryptase and chymase), and neutrophils (cathepsin G
and elastase) [19,20,26-28].
CTSC deficiency has been associated with PLS-
associated increased susceptibility to bacterial infection
in gums and other sites; however, the heterogeneous
severity of the periodontitis and the susceptibility to
infections observed in PLS suggests the existence of
compensatory pathways in most tissues [29]. The PLS
phenotype also suggests a role for CTSC in epithelial
differentiation or desquamation. Several works have
shown a relationship between CTSC and the develop-
ment of gingival fibroblasts, and the peeling of skin
keratin in affected zones [30]. Aberrant epithelial differ-
entiation may affect the junctional epithelium that binds
the gingiva to the tooth surface, possibly weakening this
mechanical barrier and allowing deeper colonization by
periodontal pathogens [30].
The Major Histocompatibility Complex (MHC) loci
(6p21.31) span nearly 3.6 Mb, and contains the most
polymorphic human genes, with strong linkage disequi-
librium. MHC products, known as Human Leukocyte
Antigens (HLA) class I (A, B and C) and class II (DP,
DQ and DR), play a key role in antigen presentation to
T-cells during elicitation of adaptive immune responses
[31]. Some PLS patients show an increased susceptibility
to recurrent suppurative infections, and several works
have attempted to associate HLA alleles with PLS and
severe periodontitis [32-34].
In México, the prevalence of PLS is unknown. Sada-
Tamayo et al. reported three cases of this syndrome in the
Mexican state of Tamaulipas in 2007 [35]. We have found
twenty PLS patients in the state of Sinaloa, indicating a high
prevalence of the disease in this region. In this work, we re-
port the clinical characteristics, gene expression, enzymatic
activity and mutational analysis of CTSC in nine PLS
patients (from seven different families) and their relatives.
Frequencies of CTSC gene polymorphisms and HLA alleles
were determined in these patients, their relatives and the
population.Methods
Study subjects
We have diagnosed twenty patients with Papillon-Lefèvre
Syndrome at the Hospital Pediátrico de Sinaloa (HPS)
level 2, but only nine were available to participate in this
study. These nine patients were born to seven non-related
families from the following locations at the northwestern
Mexican state of Sinaloa: La Reforma (two families), Las
Aguamitas, Higueras de Abuya, Sinaloa de Leyva, Navolato
and Culiacán. Parents (n = 12) and siblings (n = 5) of the
patients, and unrelated healthy individuals (n = 8) were
included in the study as comparisons. Voluntary blood
donors (n = 200) from the Instituto Mexicano del Seguro
Social (IMSS) were included for population analysis. All
subjects were natives of Sinaloa for two previous genera-
tions. The Ethical and Research Committee of HPS
approved this study and subjects signed an informed
consent.Cell isolation
Peripheral blood mononuclear cells (PBMCs) and
Polymorphonuclear cells (PMNs) were isolated by centri-
fugation on Polymorphprep (Axis Shield, Oslo, Norway)
following manufacturer recommendations. Contaminating
erythrocytes in pellets were lysed by adding 5 mL lipopoly-
saccharide (LPS)-free cold water for 45 seconds and imme-
diately adding 5 mL of LPS-free cold physiological saline
solution. Purity of cell fractions was assessed by directly
counting Giemsa-stained smears. Cell viability was assessed
by trypan blue exclusion-stain (Invitrogen, Carlsbad, CA,
USA), and was always >90% in all experiments of this work.Enzymatic activity
Leukocyte pellets were disrupted in 100 μL lysis buffer
(10 mM Na3PO4, 0.1% Trixon X-100) by one pulse of
sonication (100 W potency) for 5 seconds in ice, using
an ultrasonic probe Sonic Dismembrator 100 (Fisher
Scientific, Pittsburgh, PA, USA). Samples were centrifuged
at 2,500 g during 5 min at 4°C, and the supernatant were
recovered for enzymatic assays. Proteins were quantified
using the Bradford assay.
Enzymatic activity was assayed by mixing 20 μL of cell ex-
tract with 30 μL reaction buffer (100 mM Na3PO4, 2 mM
NaCl, 2 mM DTT), 30 μL dilution buffer (10 mM Na3PO4,
0.1% Trixon X-100), and 100 μL of chromogenic CTSC-
substrate (1.5 mM gly-phe-para-nitroanilide). Absorbencies
were measured at 405 nm, samples were incubated at 37°C
for 1 h, and read again. Dipeptidyl peptidase activity of sam-
ples, expressed as para-nitroanilide released (μmol/mg of
protein * hour), was determined interpolating the difference
between first and second reads in a standard curve (0.025 to
175 μmol) of pure para-nitroanilide (pNA) (Sigma-Aldrich,
St. Louis, MO, USA). Dipeptidyl peptidase activity from
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parison to all other groups.
Bovine spleen cathepsin C (0.5 μg/μL solution with
5 μg/μL BSA) (Sigma-Aldrich) was used to determine
enzyme kinetics by measuring pNA release from the
substrate. A reaction rate of 2.58 ±0.47 μmol of pNA
released per minute was estimated for pure bovine spleen
CTSC, and was similar to samples rates of 1.66 ±0.22.
Reaction conditions and inhibitor (iodoacetic acid, Sigma-
Aldrich) concentrations were determined from kinetic
assays and others reports [36,37].
Quantitative analysis of gene expression by qPCR
Purified leukocyte pellets were homogenized in 1 mL of
TRIZOL reagent (Invitrogen). Total RNA was extracted in
accordance to manufacturer’s instructions, treated with
DNase I (Invitrogen), and its integrity and concentration
were confirmed by electrophoresis and spectrophotometry,
respectively. RNA (2 μg) was annealed to Oligo-dT, and
synthesis of single-strand complementary DNA (cDNA)
was performed under standard conditions.
Quantitative Polymerase Chain Reaction (qPCR) was per-
formed following conditions previously described [38],
using a MiniOpticon Real-Time PCR Detection System
(Bio-Rad, Hercules, CA, USA). Primers to amplify 273 bp
(from exons 7 and 8) of human glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) gene (5’-TCATCCAT
GACAACTTTGGTATCG-3’; 5’-TGGCAGGTTTTTCTA
GACGGC-3’) and 125 bp (from exons 6 and 7) of CTSC
gene (5’-AGGAGGTTGTGTCTTGTAGCC-3’; 5’-AGT
GCCTGTGTAGGGGAAGC-3’) were designed with the
Primer Express 2.0 software (Applied Biosystems,
Foster City, CA, USA). Relative expression was calculated
with the 2(−Delta Delta C(T)) method [39]. Expression
level from healthy individual was set up as 1.0 for all
comparisons.
PCR-SSCP and sequencing
Genomic DNA was isolated from whole blood containing
EDTA, using the salt precipitation method [40]. The seven
exons of the CTSC gene, and their splice junctions, were
amplified by PCR, under standard conditions using a PXE
0.2 thermocycler (Thermo Electron). Sequence of primers
for exons 2 to 6 were taken from a previous report [14],
and were designed for exons 1 (5’-CGCCTCGTGGTGG
ACTCAC-3’; 5’-GCTCAAGGG CAGAAAGGACG-3’) and
7 (5’-GCAAAGAATAATG GAGCAAAGAAGA-3’; 5’-AA
TTCCCCTTTACAACT GATGCA-3’).
Mutation scanning of CTSC exons was done by single-
strand conformation polymorphism (SSCP), as described
elsewhere [41,42]. Briefly, PCR product samples were
diluted, 1:1 in loading buffer (95% formamide, 20 mM
EDTA, 0.05% bromophenol blue, and 0.05% xylene cyanol),
heated at 95°C for 5 min and immediately placed on ice.Aliquots were subjected to electrophoresis on polyacryl-
amide gel at 300 V for 3.2 h, at 10°C (±0.5). Gels were silver
stained to visualize the reannealed single-stranded PCR
products.
Amplified exons with mobility shifts were analyzed to
identify nucleotide changes by automated DNA sequencing.
Obtained sequences were compared with human CTSC
sequence reference of GenBank (NG_007952.1) using CLC
sequence viewer V6.4 software (CLC bio, Aarhus,
Denmark).
Protein homology analysis
Amino acid sequences of CTSC from human (NP_001805),
rhesus monkey (XP_001104734), cattle (AAI02116), dog
(AAD02704), house mouse (AAH67063), Norway rat
(NP_058793), zebrafish (AAH64286), African clawed frog
(NP_001080511), black tiger shrimp (ABW74905), Pacific
white shrimp (ACK57788), Marsupenaeus japonicum
(BAC57943) and Schistosoma japonicum (ACC32040), were
obtained from GenBank. Sequences were aligned and
analyzed using CLC sequence viewer (CLC bio).
Amino acid substitutions were analyzed with the
PolyPhen-2 (Polymorphism Phenotyping v2) software
(http://genetics.bwh.harvard.edu/pph2) to predict their
possible functional effect, in a scale from 0.00 (for be-
nign) to 1.00 (for deleterious).
PCR-RFLP
Exons 2 and 3 were amplified by PCR followed by
restriction fragment length polymorphism (RFLP). A
region of 339 bp from exon 2 of CTSC gene, containing
the c.203 T > G mutation, was amplified with the same
primers used for SSCP, and digested with Acu I (1 U for
2 h at 37°C), to identify wild-type T allele (202 and 139 bp
fragments) and the mutated G (loss of enzyme recognition
site). In the same way, a region of 257 bp from exon 3,
spanning the polymorphic site c.458C >T, was amplified
using a modified reverse-primer (5’-TCCTGAGAATTCT
TAAGGTCAGC-3’) to generate a recognition site for
Pvu II. After digestion (1 U for 2 h at 37°C), normal C
allele generates a 235 bp and a 22 bp fragments, while allele
T remains uncleaved. PCR products and digestion frag-
ments were visualized in silver-stained polyacrylamide or
GelRed-stained (Biotium, Hayward, CA, USA) agarose gels.
HLA typing
Molecular typing of HLA class I (HLA-A, HLA-B) and
HLA class II (HLA-DRB1, HLA-DQB1), at low resolution
procedure modality, was done by PCR sequence-specific
primers (PCR-SSP) technique, with the AB/DR/DQ SSP
UniTray kit, (Dynal, Invitrogen) following manufacturer’s
instructions, and using GoTaq Flexi DNA Polymerase
(Promega, Madison, WI, USA). Products were separated by
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(Invitrogen) was used to type the specific alleles.
Statistical analysis
Experimental data was obtained from triplicates and
presented as mean ± SD. Comparisons in gene expression
and enzymatic activity were performed with ANOVA and
Bonferroni multiple comparison test, and P values of less
than 0.05 were considered statistically significant. A popula-
tion sample of 96 individuals was calculated to estimate the
frequency of CTSC gene polymorphisms in the population.
Differences in allele frequencies were evaluated by χ2 test
or Fisher’s exact test. Significant P values (≤ 0.05) were
corrected taking into account the number of alleles
observed [43]. Odds ratios (OR) with 95% confidence inter-
vals (CI) were used as the measure of association between
specific alleles with PLS [44]. Hardy-Weinberg’s equilib-
rium was calculated by χ2 test. PASW v18.0 (SPSS inc.,
Chicago, IL, USA) and Arlequin v3.5.1.2 (Swiss National




The nine PLS-diagnosed patients described in this work
showed keratosis palmoplantaris, with affected knees and
elbows, and aggressive periodontitis with variable presenta-
tion. They were born (first or second gestation) to non-
consanguineous parents. Ages ranged from 1.5 to
61 years (median = 9), 55.56% were female and 44.44%
male. Panoramic and periapical radiographs confirmed
the alveolar bone loss in periodontal disease, and were
used to follow-up with patients after dental treatments.
Some patients showed increased susceptibility to pyo-
derma, such as furuncles and cold abscesses. Standard
microbiologic tests showed the presence of Aggregatibacter
actinomycetemcomitans and Staphylococcus aureus in
lesions. Infections were treated with clindamycin with
positive results. Periodontitis and hyperkeratosis severities
did not correlate. Hyperkeratosis was treated with topical
keratolytics containing salicylic acid and urea, resulting in
notable improvement of condition. Routine blood and
biochemical laboratory tests were within normal limits.
Case 1P1: 7 year-old female, showed overt palmoplan-
tar hyperkeratosis, with fissures. She had only one
deciduous tooth remaining, but her gums still showed
signs of swelling and inflammation. She suffered recurrent
folliculitis and furuncles. Case 1P2: 11 year-old female, with
mild hyperkeratosis. She had severe periodontitis, and
suffered recurrent bacterial skin infections. Case 1P3:
61 year-old male (uncle of the father of cases 1P1 and 1P2),
with mild hyperkeratosis. He had lost all his permanent
teeth, and gums appeared healthy. Case 2P: 14 year-old
male (Figure 1A), showed overt hyperkeratosis and severeperiodontitis. X-ray films of both hands discarded arachno-
dactyly, discarding Haims-Munk Syndrome. Case 3P:
6 year-old female, with mild hyperkeratosis. She developed
periodontitis just after initiation of primary dentition. Case
4P: 12 year-old female, showed mild hyperkeratosis and
severe periodontitis, and lost most of the permanent
teeth. Case 5P: 12 year-old female (Figure 1B), with mild
hyperkeratosis. She had periodontitis and loss of many
permanent teeth, malformed and decaying teeth were
observed. Case 6P: 3 year-old male (Figure 1C), showed
overt hyperkeratosis. Primary dentition has not occurred
yet and gums appeared healthy. Case 7P: 18-month-old
male, first gestation, showed mild hyperkeratosis. Primary
dentition has not occurred yet and gums appeared healthy.
CTSC activity and gene expression
Enzymatic activity and gene expression (Table 1) were
measured in PLS patients (n = 7), their relatives (n = 17)
and unrelated healthy individuals (n = 8). Patients showed
14.89% (±4.96) of the enzymatic activity observed by
controls (100%), while parents and siblings showed 47.60%
(±19.74) and 38.42% (±24.90), respectively. This represents
an enzymatic deficiency of nearly 85% in patients, and
nearly 50% in parents and siblings.
Quantification of CTSC expression showed no significant
differences (P > 0.05) among all groups. Relative expression
in comparison to controls (set up as 1.0) was 0.90 (±0.86),
1.21 (±0.86) and 0.58 ±0.43 for patients, parents and
siblings, respectively.
Mutational analyzes of CTSC
The coding sequences and splice junctions of CTSC gene
were analyzed by SSCP in nine PLS patients and their
relatives. There were changes in reannealed products in
exons 2 and 3 from patients and relatives (Figure 2A).
As expected, there were no changes in any exon in eight
unrelated healthy individuals. On sequencing (nt 177 to
228 of exon 2, and nt 433 to 484 of exon 3), nucleotide
changes were found at positions 203 (T >G) of exon 2 and
458 (C >T) of exon 3 (Figure 2B). All sequence variants were
submitted to GenBank nucleotide database (JQ763324-77)
and to dbSNPs (rs199474831).
Cases 2P and 4P were found to be compound hetero-
zygous for mutations c.203 T >G and c.458C >T, while
all other patients were found to be homozygous (G/G)
for mutation c.203 T >G. All parents and four siblings
were carriers of either c.203 T >G or c.458C >T, but not
affected (Table 1).
Protein homology analysis
DNA sequence analysis revealed that c.203 T >G mutation
is located in the exclusion domain of DPPI, resulting in a
change of the amino acid Leucine for Arginine at residue
68 (p.Leu68Arg). The presence of Arginine at this site may
Figure 1 Representative clinical features of patients with Papillon-Lefèvre Syndrome. A) Case 2P: Overt hyperkeratosis in hands
(dorsal view). With gingivitis, missing teeth and periodontal pocket. B) Case 5P: Mild hyperkeratosis of sole and mobile teeth. C) Case 6P:
Psoriasiform lesions over palms and knees.
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subsequently blocking the enzymatic activity. In fact,
homology analysis showed that Leucine 68 is a highly
conserved residue, and analysis of this substitution with
the PolyPhen-2 software predicted a damaging mutation,
with a score of 1.00.
The substitution c.458C > T results in a change of
the amino acid Threonine for Isoleucine at residue 153
(p.Thr153Ile); this residue is not highly conserved in
evolution and is located in the pro-region of heavy chain,
which is removed during DPPI activation. PolyPhen-2
software predicted a probably benign mutation with a
score of 0.00.
Population frequencies of CTSC gene polymorphisms
PCR-SSCP analyzes of CTSC exons 2 and 3 were done in
individuals from the population (n = 200). Positive samples
were confirmed for mutations c.203 T >G and c.458C >T
by PCR-RFLPs (Figure 3).
Allelic frequencies in PLS patients (n = 9), their relatives
(n = 17) and controls were 88.89%, 38.24% and 0.25% for
G (c.203 T >G), respectively; and 11.11%, 8.82% and
9.00% for T (c.458C > T). Genotypes frequencies of
c.203 T >G were 77.78%, 0.0% and 0.0% for G/G; 22.22%,
76.47% and 0.5% for T/G; and 0.0%, 23.53% and 99.5% forT/T. For c.458C > T genotypes, frequencies were 22.22%,
17.65% and 18.0% for C/T; and 77.78%, 82.35, and 82.0%
for C/C (Table 2). The distributions of c.203 T >G and
c.458C > T polymorphisms in the groups were in Hardy-
Weinberg equilibrium (all P > 0.05).
For c.203 T >G there were significant differences in al-
lelic (P = 0.0000; OR = 3192.00; 95% CI = 274.92-37061.06)
and genotypic (P = 0.0000) frequencies between patients
and population controls and in alleles (P = 0.0000; OR =
247.00; 95% CI = 30.83-1978.58) and genotypes (P = 0.0000)
between patients’ relatives and controls. For c.458C >T
alleles and genotype distributions there were no significant
differences between all groups (all P > 0.05).
The initial calculated sample size for population analysis
was 96, however, an individual carrying a heterozygous T/G
genotype for c.203 T >G was found, and therefore a final
sample of 200 individuals was used.
Immunogenetics
HLA alleles were typed in PLS patients (n = 9), their
relatives (n = 15) and population controls (n = 41)
(Table 3). The more common HLA alleles found in
patients and controls were 33.33% vs. 14.63% (P = 0.0873;
OR = 2.92; 95% CI = 0.92-9.26) for HLA-A*24, and 16.67%
vs. 29.27% (P = 0.2755) for A*02. HLA-B*35 was found in
Table 1 Percentage of cathepsin C activity, gene expression, and genotypes in patients with Papillon-Lefèvre
Syndrome and their relatives
Family Subject % SD P CE SD P c.203 T > G c.458C > T
1 1P1 13.45 2.97 0.0001 0.25 0.05 0.0070 G/G C/C
1P2 - - - - - - G/G C/C
1P3 - - - - - - G/G C/C
1 F 46.99 1.40 0.0041 1.62 0.05 0.0110 T/G C/C
1 M 67.93 2.76 0.0489 0.31 0.11 0.0170 T/G C/C
2 2P 11.03 4.41 0.0061 1.81 0.09 0.0750 T/G C/T
2 F 59.22 5.76 0.1580 2.99 1.07 0.1190 T/G C/C
2 M 42.91 5.01 0.0561 0.42 0.09 0.1190 T/T C/T
2B1 39.26 3.25 0.0438 0.37 0.06 0.1000 T/T C/T
2B2 - - - 1.33 0.01 0.1440 T/T C/C
3 3P 24.16 1.33 0.0000 1.39 0.66 0.4280 G/G C/C
3 M 55.76 0.90 0.0000 0.44 0.07 0.0070 T/G C/C
4 4P 14.97 0.10 0.0013 0.19 0.01 0.0080 T/G C/T
4 M 27.75 0.10 0.0018 1.40 0.08 0.0470 T/T C/T
4S 72.64 0.16 0.0106 0.57 0.11 0.0560 T/G C/C
4B 26.93 0.17 0.0017 0.29 0.11 0.0210 T/G C/C
5 5P 15.32 2.12 0.0000 0.15 0.00 0.0570 G/G C/C
5 F 77.74 12.07 0.0608 2.55 1.81 0.2900 T/G C/C
5 M 56.50 1.26 0.0016 0.46 0.05 0.1260 T/G C/C
6 6P 10.42 0.86 0.0000 0.34 0.12 0.1030 G/G C/C
6 F 16.92 2.01 0.0000 1.37 0.57 0.0177 T/G C/C
6 M 24.23 7.85 0.0000 1.32 0.39 0.0123 T/G C/C
6S 14.84 3.61 0.0000 0.34 0.21 0.0002 T/G C/C
7 7P - - - 2.15 0.10 0.0410 G/G C/C
7 F - - - 0.57 0.18 0.2220 T/G C/C
7 M - - - 1.06 0.79 0.8020 T/G C/C
%, percentage of enzymatic activity in relation to healthy individuals (set as 100%). CE, cathepsin C expression in relation to healthy individuals (set up as 1.0).
P, p value from comparison to healthy individuals. (−), sample not available. Subjects: P, patient; F, father; M, mother; B, brother: S, sister. SD, standard deviation.
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11.11% vs. 10.98% (P = 0.9867). Frequencies of HLA-
DRB1*11 were 33.33% vs. 7.32% (P = 0.0071; OR = 6.33;
95% CI = 1.75-22.89), and 22.22% vs. 24.39% (P = 0.8454)
for DRB1*04. Frequencies for HLA-DR53, DR52 and DR51
were 44.44% vs. 41.46% (P = 0.8165), 33.33% vs. 21.95%
(P= 0.3059), and 22.22% vs. 24.39% (P= 0.8454), respectively.
For HLA-DQB1*0301, frequencies were 33.33% vs.
24.39% (P = 0.2715), and 27.08% vs. 17.07% (P = 0.1745)
for DQB1*0302. Significant deviations from Hardy–
Weinberg equilibrium were not detected in the distribution
of HLA alleles (all P > 0.05).
Discussion
Here we described the clinical profile of nine patients
(belong to seven different families) with Papillon-
Lefèvre Syndrome (PLS), from the northwestern Mexican
state of Sinaloa. They showed keratosis palmoplantaris andaggressive periodontitis with variable expression, which are
the classical features of this syndrome [45]. In contrast to
the nearly 30% of consanguinity of PLS cases reported in
different countries [2,3], our PLS patients were born to
non-consanguineous parents, and their families were not
related.
PLS patients showed a DPPI activity reduction up to
85%, while parents and siblings showed a partial reduction
of nearly 50%. This enzymatic deficiency was not due to
diminished CTSC gene expression levels, as no significant
differences were found between all groups. In agreement
with our findings, more than 80% of all PLS cases reported
show CTSC deficiency due to gene mutations [14,34].
Zhang et al. found less than 10% of the normal enzymatic
activity in PLS patients and 50% in parents [46]. To our
knowledge, there are no reports of CTSC messenger quan-
tification using qPCR technique for this purpose in the
literature.
Figure 2 Mutational analysis of Cathepsin C gene. A) Representative results of CTSC gene exon scanning by single-strand conformation
polymorphism (SSCP). Reannealed products, in silver-stained polyacrylamide gels, of exons 2 (left) and 3 (right) in cases 6P and 4P showed
differences (arrows) against controls 2 and 6. B) Representative electropherograms of exon 2 showing genotypes (arrows) homozygote normal
T/T (control 1), heterozygote T/G (parent 1 F) and homozygote mutated G/G (case 1P1), for mutation c.203 T > G. Exon 3, showing
genotypes (arrows) homozygote normal C/C (control 4) and heterozygote C/T (case 2P) for polymorphism c.458C > T.
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Figure 3 Gene polymorphisms analysis. PCR-RFLPs products of
genotypes homozygous normal T/T, heterozygous T/G and
homozygous mutated G/G for mutation c.203 T > G of exon 2 (left).
Genotypes homozygous normal C/C and heterozygous C/T, for
c.458C > T polymorphism of exon 3 (right). M, 50 bp DNA ladder
(Invitrogen).
Table 3 Allele frequencies (af) of the more common HLA
class I and II molecules found in patients with Papillon-
Lefèvre Syndrome, their relatives and controls
Alleles Patients Relatives Controls
(N = 18) (N = 30) (N = 82)
HLA-A af af af
A*24 6 0.3333 8 0.2667 12 0.1463
A*02 3 0.1667 4 0.1333 24 0.2927
A*33 3 0.1667 2 0.0667 1 0.0122
A*31 2 0.1111 5 0.1667 8 0.0976
A*03 2 0.1111 2 0.0667 2 0.0244
HLA-B
B*35 6 0.3333 9 0.3000 17 0.2073
B*65 3 0.1667 2 0.0667 2 0.0244
B*44 2 0.1111 2 0.0667 9 0.1098
B*51 1 0.0556 2 0.0667 4 0.0488
B*60 1 0.0556 2 0.0667 3 0.0366
HLA-DRB1
DRB1*11 6 0.3333 6 0.2000 6 0.0732
DRB1*04 4 0.2222 9 0.3000 20 0.2439
DRB1*01 3 0.1667 6 0.2000 13 0.1585
DRB1*15 3 0.1667 4 0.1333 3 0.0366
DRB1*07 1 0.0556 2 0.0667 8 0.0976
HLA-DQB1
DQB1*0301 7 0.3889 9 0.3000 20 0.2439
DQB1*0302 4 0.2222 9 0.3000 14 0.1707
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gous for c.203 T >G and c.458C >T, while all other cases
were found to be homozygous for c.203 T >G. Of note, all
parents, as well as four siblings, carried either c.203 T >G
or c.458C >T. These findings could explain the reduction
in DPPI activity observed in these subjects, and seems
to confirm the autosomal recessive mode of inheritance
of PLS.
According to the Human Gene Mutation Database
(HGMD), 77 variants of the CTSC gene have beenTable 2 Allelic (af) and genotypic (gf) frequencies of
cathepsin C polymorphisms in patients with Papillon-
Lefèvre Syndrome, their relatives and controls
Polymorphism Patients Relatives Controls
c.203 T > G
Alleles n = 18 af n = 34 af n = 400 af
G 16 0.8889 13 0.3824 1 0.0025
T 2 0.1111 21 0.6176 399 0.9975
Genotypes n = 9 gf n = 17 gf n = 200 gf
G/G 7 0.7778 0 0.0000 0 0.0000
T/G 2 0.2222 13 0.7647 1 0.0050
T/T 0 0.0000 4 0.2353 199 0.9950
c.458C > T
Alleles n = 18 af n = 34 af n = 400 af
T 2 0.1111 3 0.0882 36 0.0900
C 16 0.8889 31 0.9118 364 0.9100
Genotypes n = 9 gf n = 17 gf n = 200 gf
T/T 0 0.0000 0 0.0000 0 0.0000
C/T 2 0.2222 3 0.1765 36 0.1800
C/C 7 0.7778 14 0.8235 164 0.8200
DQB1*0501 4 0.2222 4 0.1333 9 0.1098
DQB1*0601 2 0.1111 2 0.0667 8 0.0976
DQB1*0201 1 0.0556 5 0.1667 14 0.1707reported. The c.203 T >G substitution we report here, is a
novel loss-of function mutation, and associates with the
diminished enzymatic activity observed in our PLS patients.
In accordance, frequency of allele G (c.203 T >G) was
higher in patients and relatives in comparison to population
controls (all P ≤ 0.05).
The substitution c.458C > T has been reported as both
a common polymorphism in some populations, and as
causal mutation in PLS patients [47-49]. c.458C > T has
been reported as causal mutation in one Australian PLS
patient (compound heterozygous for c.458C > T and
c.199_222del) [49]. However, a genotypic study for the
c.458C > T polymorphism in the Spanish population
reported frequencies of 81% for homozygote normal
and 19% for heterozygote [47]. In accordance, allele T
(c.458C > T) was found relatively frequent in our popu-
lation (9%), with no significant differences between the
studied groups, and PolyPhen-2 software predicted a
probably benign mutation. Therefore, the results of
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variant other than c.203 T > G remains unidentified in
the coding region.
Some patients in this study showed increased suscep-
tibility to bacterial skin infections. This condition seems
to be due to an impairment of the immune system,
which is involved in the pathoetiology of PLS. Therefore,
we genotyped HLA class I and II alleles of PLS patients,
their relatives and controls to evaluate any particular HLA
association with this disease. We found fourteen HLA-A,
twenty-nine HLA-B, twelve HLA-DRB1 and six HLA-
DQB1 alleles (online Additional file 1), with HLA-A*02,
B*35, DRB1*04, and DQB1*0301 being the most frequent
in the population. A common HLA-A/B/DR/DP haplotype
was not found in the families, confirming the lack of
relationship among them.
With exception of HLA-DRB1*11, our results are in
agreement with other reports showing no particular
association of HLA alleles with PLS [32,34]. We found
that HLA-DRB1*11 allele was significantly more frequent
(P = 0.0071) in our PLS patients than in controls (33.33%
vs. 7.32%, respectively), resulting in an estimated relative
risk index of 6.33. Interestingly, this allele has been also
associated with scleroderma in Caucasian patients [50].
HLA-A*24(9), HLA-B*35, DRB1*04 and DR51 showed
higher frequency in our PLS patients than in controls,
but the differences were not statistically significant.
HLA-A*24(9) DRB1*04 and DR51 alleles have been
associated with different kinds of periodontitis in other
countries [33,51-53].
Mexicans, Mestizos in general, have a high degree of
genetic heterogeneity due to centuries of mixing with
Native Americans, Africans and Europeans. In the South
and Central parts of Mexico, the predominant HLA type
is more Amerindian than European or African, but in
Sinaloa, half of the most common HLA haplotypes are
believed to be of European origin. Allelic frequencies of
the population found in this work were in accordance
with a previous report [54]. An important difference is
that our more extensive molecular study had included, for
the first time, the side-by-side comparison of PLS families
with unrelated, healthy controls.
Although the exact pathogenesis of PLS is still unknown,
biochemical and genetic analysis allows for genetic
counseling and opportune treatment, especially for those
patients with familial history of this disease. Furthermore,
some authors believe that if treatment is started at an early
age, patients would possibly have normal adult dentition
[55]. One of the studied cases (7P) is only 18-months-old,
and will be under treatment and observation to avoid
serious complications.
While in México the general prevalence of this syndrome
is still unknown, and the number of reported cases is very
low, the finding so far of 20 patients in the state of Sinaloahighlights the need for more studies of this nature. Due to
the concentrated number of PLS patients found in our
population, none of them previously described, is would be
possible to argue that there is a founder effect for CTSC
gene mutation. An haplotype analysis of DNA markers in
CTSC gene region can help to determine if c.203 T >G
mutation has this founder effect.
Conclusion
In conclusion, our work describes the immunogenetics,
and the biochemical and molecular characterization of
CTSC in nine PLS patients and their families. We describe
the identification of a novel loss-of function mutation in
CTSC gene (c.203 T >G) causing PLS in Mexican patients;
and the association of the HLA-DRB1*11 allele with this
syndrome. The study of more PLS patients may give
more insights into the etiology of the disease as well as
its prevalence in México.
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